Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

81. Cladribine (Mavenclad) - for the treatment of adult patients with highly active relapsing multiple sclerosis (MS)

Cladribine (Mavenclad) - for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) Cost-effectiveness of cladribine (Mavenclad®) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features The NCPE has issued a recommendation regarding the cost-effectiveness of cladribine (Mavenclad®). Following assessment of the applicant’s submission, the NCPE recommends that cladribine (Mavenclad® (...) who has a responsibility for commissioning or providing healthcare, public health or social care services. National Centre for Pharmacoeconomics July 20182 Summary In December 2017, Merck Serono Europe Ltd submitted a dossier of clinical, safety and economic evidence in support of cladribine (Mavenclad®) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features. This includes both relapsing remitting MS (RRMS) and secondary

2018 Pediatric Endocrine Society

82. Ocrelizumab (Ocrevus) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)

Ocrelizumab (Ocrevus) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) Cost-effectiveness of ocrelizumab (Ocrevus®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) The NCPE has issued a recommendation regarding the cost-effectiveness of Ocrelizumab (Ocrevus) for the treatment of relapsing – remitting multiple sclerosis (RRMS). Following assessment of the applicant’s submission, the NCPE recommends that ocrelizumab (...) , safe and value for money treatments for patients. Our advice is for consideration by anyone who has a responsibility for commissioning or providing healthcare, public health or social care services. National Centre for Pharmacoeconomics August 20182 Summary Roche Products Ireland Ltd submitted an economic dossier on the cost-effectiveness of ocrelizumab (Ocrevus®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) on the 16 th March 2018. Ocrelizumab

2018 Pediatric Endocrine Society

83. Ocrelizumab (Ocrevus) for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS)

Ocrelizumab (Ocrevus) for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) Cost-effectiveness of ocrelizumab (Ocrevus®) for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) The NCPE has issued a recommendation regarding the cost-effectiveness of ocrelizumab (Ocrevus®) for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS). Following assessment of the applicant’s submission (...) primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. Ocrelizumab is a humanised monoclonal antibody that selectively targets CD20 a cell surface antigen expressed on B cells but not on lymphoid stem cells or plasma cells. It was granted regulatory approval from the European Medicines Agency (EMA) on the 8 th January 2018. The formulation is ocrelizumab 300mg concentrate for solution

2018 Pediatric Endocrine Society

84. Multiple sclerosis

Multiple sclerosis Multiple sclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Multiple sclerosis Last reviewed: February 2019 Last updated: February 2019 Summary Demyelinating central nervous system condition clinically defined by two episodes of neurological dysfunction (brain, spinal cord, or optic nerves) that are separated in space and time. Classically presents in white women, aged between 20 to 40 years (...) , but lends greater specificity when present with brain lesions. Treatment of the condition can be divided into three parts: treatment of the acute attack; prevention of future attacks by reducing triggers and use of disease-modifying therapies; and symptomatic treatments of neurological difficulties such as spasticity, pain, fatigue, and bladder dysfunction. Definition Multiple sclerosis (MS) is defined as an inflammatory demyelinating disease characterised by the presence of episodic neurological

2018 BMJ Best Practice

85. Ocrelizumab (Ocrevus) - multiple sclerosis

Ocrelizumab (Ocrevus) - multiple sclerosis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 9 November 2017 EMA/790835/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Ocrevus International non (...) Chain LC-MS Liquid Chromatography - Mass Spectrometry; LC-UV Liquid Chromatography - Ultraviolet; LMWS Low-Molecular-Weight Species; LPA Leached Protein A LPM Liters Per Minute;. LRV Log Reduction Value MAR Multivariate Acceptable Range MCB Master Cell Bank MMV Murine Minute Virus Mn2+ Manganese MS Multiple Sclerosis MTX methotrexate NA Not Applicable NANA N-acetylneuraminic acid;; NEM N-ethylmaleimide NF National Formulary NGHC Non-glycosylated Heavy Chain. NGNA N-glycolylneuraminic acid; non-CPP

2018 European Medicines Agency - EPARs

86. Mavenclad - cladribine - Multiple Sclerosis, relapsing

Mavenclad - cladribine - Multiple Sclerosis, relapsing cladribine | CADTH.ca Find the information you need cladribine cladribine Last Updated: November 27, 2018 Result type: Reports Project Number: SR0546-000 Product Line: Generic Name: cladribine Brand Name: Mavenclad Manufacturer: EMD Serono, a Division of EMD Inc., Canada Indications: Multiple Sclerosis, relapsing Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: October 24, 2018 Recommendation Type (...) Recommendation posted October 26, 2018 Final CDR review report(s) and patient input posted October 31, 2018 Tags multiple sclerosis, nervous system, multiple sclerosis, relapsing-remitting, cladribine; RRMS Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

87. Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis

Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis NHS England » Urgent Clinical Commissioning Policy Statement: Natalizumab-induced Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis (all ages) Search Search Menu Urgent Clinical Commissioning Policy Statement: Natalizumab-induced (...) Progressive Multifocal Leukoencephalopathy in relation to Immune Reconstitution Inflammatory Syndrome in Multiple Sclerosis (all ages) Document first published: 14 March 2018 Page updated: 14 March 2018 Topic: , Publication type: This clinical commissioning policy statement is an interim commissioning position pending the formation of a Clinical Policy. Document PDF 74 KB 5 pages

2018 NHS England

88. Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Extract 1 Translation of the executive summary of the dossier assessment Extrakt aus Cannabis sativa (Spastik aufgrund von multipler Sklerose) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 26 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG (...) to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-27 Extract from Cannabis sativa (spasticity due to multiple sclerosis) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A18-27 Version 1.0 Extract from Cannabis sativa (spasticity due to multiple sclerosis) 26 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

89. Multiple sclerosis

Multiple sclerosis Multiple sclerosis - NICE CKS Share Multiple sclerosis: Summary Multiple sclerosis (MS) is a presumed autoimmune inflammatory condition of the central nervous system (CNS) resulting in areas of demyelination (damage to white matter), gliosis (subsequent scarring), and secondary neuronal damage (cell loss) throughout the CNS. Typically, MS first develops in young adults and is the most common non-traumatic cause of significant neurological disability in people younger than 40 (...) published by the National Institute for Health and Care Excellence (NICE) Multiple sclerosis: management of multiple sclerosis in primary and secondary care [ ]. This CKS topic covers the diagnosis and referral of people with suspected multiple sclerosis, and appropriate treatment of symptoms and complications that may come under the remit of primary care. This CKS topic does not cover the details of secondary care treatments, including disease modifying therapies. The target audience for this CKS topic

2018 NICE Clinical Knowledge Summaries

90. Cladribine tablets for treating relapsing?remitting multiple sclerosis

Cladribine tablets for treating relapsing?remitting multiple sclerosis Cladribine tablets for treating Cladribine tablets for treating relapsing–remitting multiple sclerosis relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

92. PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage

PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage | European Medicines Agency Search Search Menu PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage Press release 27/10/2017 Zinbryta to be used only in a restricted patient group, with strict liver monitoring (...) EMA's ( ) is recommending further restrictions on the use of the multiple sclerosis medicine Zinbryta (daclizumab) following a review of the medicine's effects on the liver. The review found that unpredictable and potentially fatal immune-mediated liver injury can occur during treatment with Zinbryta and for up to 6 months after stopping treatment. In , 1.7% of patients receiving Zinbryta had a serious liver reaction. In order to reduce the risks, doctors should now only prescribe Zinbryta

2017 European Medicines Agency - EPARs

93. Antineutrophil Cytoplasmic Antibody and Multiple Sclerosis Full Text available with Trip Pro

Antineutrophil Cytoplasmic Antibody and Multiple Sclerosis 29854982 2019 02 26 2468-0249 3 3 2018 May Kidney international reports Kidney Int Rep Antineutrophil Cytoplasmic Antibody and Multiple Sclerosis. 732-737 10.1016/j.ekir.2017.11.013 George Jason C JC Department of Nephrology, Geisinger Medical Center, Danville, Pennsylvania, USA. Mohan Prince P Department of Nephrology, Geisinger Medical Center, Danville, Pennsylvania, USA. Ho Kevin K Department of Nephrology, Geisinger Medical Center

2017 Kidney international reports

94. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality (Abstract)

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality To investigate the effect of chronic comorbidity on the time of diagnosis of multiple sclerosis (MS) and on mortality in MS.We conducted a population-based, nationwide cohort study including all incident MS cases in Denmark with first MS symptom between 1980 and 2005. To investigate the time of diagnosis, we compared individuals with and without chronic comorbidity using multinomial logistic

2017 EvidenceUpdates

95. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Full Text available with Trip Pro

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Multiple sclerosis is a degenerative inflammatory disease of the CNS characterised by immune-mediated destruction of myelin and progressive neuroaxonal loss. Myelin in the CNS is a specialised extension of the oligodendrocyte plasma membrane and clemastine fumarate can stimulate differentiation of oligodendrocyte precursor cells in vitro, in animal models (...) , and in human cells. We aimed to analyse the efficacy and safety of clemastine fumarate as a treatment for patients with multiple sclerosis.We did this single-centre, 150-day, double-blind, randomised, placebo-controlled, crossover trial (ReBUILD) in patients with relapsing multiple sclerosis with chronic demyelinating optic neuropathy on stable immunomodulatory therapy. Patients who fulfilled international panel criteria for diagnosis with disease duration of less than 15 years were eligible. Patients were

2017 Lancet Controlled trial quality: predicted high

96. Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation

Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation Melendez-Torres G, Auguste P, Armoiry X, Maheswaran (...) -effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment 2017; 21(52) Authors' objectives To undertake (1) systematic reviews of the clinical effectiveness and cost-effectiveness of IFN-β and GA in relapsing–remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS) compared with best supportive care (BSC) and each other, investigating

2017 Health Technology Assessment (HTA) Database.

97. Cladribine (Mavenclad) - multiple sclerosis

Cladribine (Mavenclad) - multiple sclerosis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 22 June 2017 EMA/435731/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report MAVENCLAD International non-proprietary name: cladribine Procedure No. EMEA/H/C/004230/0000 Note Assessment report as adopted (...) Area under the curve BCRP Breast cancer resistant protein, ATP-binding cassette transporter ABCG2 CDMS Clinically Definite Multiple Sclerosis CI Confindence Interval CIS Clinically Isolated Syndrome CL clearance CNS Central Nervous System c max maximum plasma concentration CYP Cytochrome DB Double-Blind DCK Deoxycytidine kinase DMD Disease Modifying Drug EAE Experimental Autoimmune Encephalomyelitis EDSS Expanded Disability Status Scale EMA European Medicines Agency Emax inhibitory maximum exposure

2017 European Medicines Agency - EPARs

98. Response to 'Foix-Alajouanine is another differential diagnosis in longitudinal myelitis thought to be a case of multiple sclerosis or neuromyelitis optica' Full Text available with Trip Pro

Response to 'Foix-Alajouanine is another differential diagnosis in longitudinal myelitis thought to be a case of multiple sclerosis or neuromyelitis optica' 28868157 2019 01 15 2058-6124 3 2017 Spinal cord series and cases Spinal Cord Ser Cases Response to 'Foix-Alajouanine is another differential diagnosis in longitudinal myelitis thought to be a case of multiple sclerosis or neuromyelitis optica'. 17059 10.1038/scsandc.2017.59 Suthiphosuwan Suradech S St Michael's Hospital, University

2017 Spinal cord series and cases

99. Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data Full Text available with Trip Pro

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data Data on comparative healthcare resource utilization and costs associated with the newer oral disease-modifying therapies (DMTs) for managing relapsing-remitting multiple sclerosis (MS) in routine clinical practice are limited. The purpose of this study was to estimate healthcare resource utilization, costs, and relapse

2017 PharmacoEconomics open

100. Perceived Exertion Is Lower When Using a Functional Electrical Stimulation Neuroprosthesis Compared With an Ankle-Foot Orthosis in Persons With Multiple Sclerosis: A Preliminary Study. (Abstract)

Perceived Exertion Is Lower When Using a Functional Electrical Stimulation Neuroprosthesis Compared With an Ankle-Foot Orthosis in Persons With Multiple Sclerosis: A Preliminary Study. This study investigates the direct comparison of energy cost, efficiency, and effort between an ankle-foot orthosis (AFO) and a functional electrical stimulation (FES) device for foot drop in ambulatory patients with multiple sclerosis.Twenty adults (32-74 years old; 55% female) with a diagnosis of multiple (...) -assessment activity and evaluation online at http://www.physiatry.org/JournalCME CME OBJECTIVES: Upon completion of this article, the reader should be able to: (1) describe the potential differences between an AFO and FES for the treatment of foot drop in patients with multiple sclerosis, (2) understand the mechanisms and prevalence of foot drop in patients with multiple sclerosis, and (3) recognize the potential benefit of improved perceived exertion found when using FES for the treatment of foot drop

2017 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain